21st Aug 2007 11:59
ReGen Therapeutics PLC21 August 2007 REGEN THERAPEUTICS PLC ("ReGen" or the "Company"; Ticker: (RGT)) TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): ReGen Therapeutics Plc 2. Reason for the notification: An acquisition or disposal of voting rights 3. Full name of person(s) subject to the notification obligation (iii): Andrew Clement Wilson 4. Full name of shareholder(s) (if difference from 3): As above 5. Date of the transaction and date on which the threshold is crossed or reached (v): 16 July 2007 6. Date on which issued notified: 21 August 2007 7. Threshold(s) that is/are crossed or reached: 3% 8. Notified details A: Voting rights attached to shares Class/type of share if possible using the ISIN Code GB0004468319 Situation Previous to the triggering transaction (vi) - Number of Shares 30,505,000 Number of Voting Rights (viii) 30,505,000 Resulting situation after the triggering transaction (viii) - Number of Shares 30,855,000 Number of Voting Rights - Direct (x) N/A Number of Voting Rights - Indirect (xi) 30,855,000 % of voting rights - Direct N/A % of voting rights - Indirect 3.01 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of financial instrument N/A Expiration date (xiii) N/A Exercise/Conversion Period/Date (xiv) N/A Number of voting rights that may be acquired if theinstrument is exercised/converted N/A % of voting rights N/A Total (A+B) Number of voting rights 30,855,000 % of voting rights 3.01 9. Chain of controlled undertakings through which the voting rights and/orthe financial instruments are effectively held, if applicable (xv): Shares are held in own name Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: N/A 14. Contact name: N/A 15. Contact telephone number: N/A For further information: Andrew MarshallGreycoat CommunicationsTel: +44 (0) 207 960 6007Mobile: +44 (0) 7785 297111 Percy LomaxReGen Therapeutics PlcTel: +44 (0) 207 153 4920 Andrew Baker / Cecil Jordaan / Rory CreedonHB CorporateTel: +44(0) 207 510 8600 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TILS.L